We are live on
!
Find out more
IMUC
ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC
Delisted
IMUC was delisted on the 16th of October, 2018.
20 hedge funds and large institutions have $464K invested in ImmunoCellular Therapeutics, Ltd. in 2018 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
13% less funds holding
Funds holding: 23 → 20 (-3)
23% less capital invested
Capital invested by funds: $601K → $464K (-$137K)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Holders
20
Holders Change
-3
Holders Change %
-13.04%
% of All Funds
0.46%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.4K |
| 2 |
Renaissance Technologies
New York
|
+$14.6K |
| 3 |
Invesco
Atlanta,
Georgia
|
+$3.21K |
| 4 |
RCAG
Rehmann Capital Advisory Group
Lansing,
Michigan
|
+$18 |
Top Sellers
| 1 |
Millennium Management
New York
|
-$94K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$67.2K |
| 3 |
VF
Virtu Financial
New York
|
-$27.9K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$10K |
